Apollo Hospitals Enterprise Ltd share Price

Apollo is one of the leading integrated healthcare service provider with avenues like hospitals, pharmacies, primary care & diagnostic clinics.

• Group capacity of 10,033 beds across 71 hospitals in India. Total 8660 beds owned in 44 hospitals; 278 beds in 11 cradles; 244 beds in 11 day-care/short surgical stay centres; 851 beds in five hospitals under O&M contracts
• It has got a digital presence with “ASK Apollo” & digital health platform “Apollo 24/7”. Apollo Hospitals is the exclusive supplier for APL, which operates India’s largest standalone pharmacy chain with 4,390 outlets
• Apollo Health & Lifestyle Ltd runs the largest chain of standardised primary healthcare models, multi-specialty clinics under the brand: Apollo Clinics in India and Middle East, diabetes management clinics: Apollo Sugar, diagnostic centres: Apollo Diagnostics, specialty formats: Apollo Cradle for women & children, Apollo Spectra for planned surgery

Apollo reported in-line results but skewed with Hospitals lagging our expectations but pharmacies a beat on our estimates.

• Revenues increased 31.9% YoY to ₹ 3638.9 crore
• EBITDA was at ₹ 587 crore, up 50.4% YoY with margins at 16.1%
• Adjusted PAT was at ₹ 228.4 crore (up 75.1% YoY)

Healthcare Facilities company Apollo Hospitals Enterprise announced Q4FY23 & FY23 results:

• Q4FY23:
  • Revenues grew 21% to Rs 43,022 million vs Rs 35,464 million in Q4FY22
  • EBITDA excluding 24/7 Operating Cost and ESOP charge stood at Rs 706 million; 29% YoY growth
  • Apollo 24/7 cost of Rs 2,174 million in the quarter (including Rs 281 million non-cash ESOP charge) vs Rs 841 million in Q4FY22
  • EBITDA post 24/7 Operating Cost and ESOP charge at Rs 4,882 million vs Rs 4,632 million in Q4FY22; 5% YoY growth
  • PAT grew 60% to Rs 1,445 million vs Rs 901 million in Q4FY23
  • Diluted EPS of Rs 10.05 per share in Q4FY23 (not annualised)
• FY23:
  • Revenues grew 13% to Rs 166,125 million vs Rs 146,626 million in FY22
  • EBITDA excluding 24/7 Operating Cost and ESOP charge stood at Rs 27,851 crore ;16% YoY growth
  • Apollo 24/7 cost of Rs 7,355 million for the full year (including Rs 781 million non-cash ESOP charge) vs Rs 2,236 million in FY22
  • EBITDA post 24/7 Operating Cost and ESOP charge at Rs 20,496 million vs Rs 21,851 million in FY22
  • PAT stood at Rs 8,191 million vs of Rs 10,556 million in FY22
  • Diluted EPS of Rs 56.97 per share in FY23

Dr. Prathap C Reddy, Chairman, Apollo Hospitals Group said, “The first full post-pandemic year has seen Apollo make some remarkable strides in its journey of healing. Our unwavering commitment to deliver world-class healthcare has enabled us to scale new heights with our performance - both in terms of financial metrics and in the expansion of our healthcare service offerings. We have seen a substantial increase in patient engagement both in our hospitals and clinics, as well as on our digital health platform Apollo 24/7.

We have continued to broaden our services, ensuring that we focus not just on cure, but on preventive healthcare as well. At a time when the world is realizing the importance of prevention more than ever before, it is a matter of pride that Apollo has been at the forefront of this shift, recognizing that the best way to fight disease is to prevent it in the first place. One of our areas of focus is Artificial Intelligence (Al), which we believe holds the power to revolutionize preventive healthcare, by helping identify patterns, predict health risks, and enable early interventions. This year, we have invested thoughtfully in Al technologies, and the results have been heartening. They have allowed us to provide a personalized healthcare approach for every individual, taking into account their unique genetic disposition, lifestyle, and medical history."

Result PDF